Chemotherapy Drug Manufacturing

Cancer is a growing public health crisis in Syria, with over 21,900 new cases annually and a critical shortage of locally produced chemotherapy drugs. This project proposes a $5 million investment to establish a state-of-the-art, GMP-compliant facility in Adra Industrial City, Damascus, dedicated to manufacturing essential injectable chemotherapy agents—cisplatin, paclitaxel, and doxorubicin.